31 related articles for article (PubMed ID: 11392099)
1. Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia.
Salazar LA; Hirata MH; Quintão EC; Hirata RD
J Clin Lab Anal; 2000; 14(3):125-31. PubMed ID: 10797611
[TBL] [Abstract][Full Text] [Related]
2. Fluvastatin for lowering lipids.
Adams SP; Sekhon SS; Tsang M; Wright JM
Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012282. PubMed ID: 29508377
[TBL] [Abstract][Full Text] [Related]
3. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Krysiak R; Okopień B; Herman Z
Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of fluvastatin, a hydroxylmethylglutaryl-coenzyme A reductase inhibitor, on coagulation and the fibrinolytic system in patients with hypercholesterolemia.
Saito M; Asakura H; Morishita E; Yamazaki M; Matsuda T
Int J Hematol; 1999 Jun; 69(4):274-6. PubMed ID: 10407589
[No Abstract] [Full Text] [Related]
5. Another view of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors and the fibrinolytic system.
Emeis JJ; Cohen LH
Am J Cardiol; 1997 Oct; 80(7):977-8. PubMed ID: 9382029
[No Abstract] [Full Text] [Related]
6. Effect of fluvastatin on lipids and fibrinolysis in coronary artery disease.
Bevilacqua M; Bettica P; Milani M; Vago T; Rogolino A; Righini V; Santoli E; Norbiato G
Am J Cardiol; 1997 Jan; 79(1):84-7. PubMed ID: 9024745
[TBL] [Abstract][Full Text] [Related]
7. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
[TBL] [Abstract][Full Text] [Related]
8. Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Liu L; Zhao SP; Zhou HN; Li QZ; Li JX
J Cardiovasc Pharmacol; 2007 Jul; 50(1):50-5. PubMed ID: 17666915
[TBL] [Abstract][Full Text] [Related]
9. The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
Lin TH; Huang CH; Voon WC; Yen HW; Lai HM; Liang HY; Lu YH; Lee KT; Lee CS; Lai WT; Sheu SH
Kaohsiung J Med Sci; 2000 Dec; 16(12):600-6. PubMed ID: 11392099
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Plosker GL; Wagstaff AJ
Drugs; 1996 Mar; 51(3):433-59. PubMed ID: 8882381
[TBL] [Abstract][Full Text] [Related]
11. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
Asberg A; Holdaas H
Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
[TBL] [Abstract][Full Text] [Related]
12. Fluvastatin: effects beyond cholesterol lowering.
Corsini A
J Cardiovasc Pharmacol Ther; 2000 Jul; 5(3):161-75. PubMed ID: 11150405
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
